Evidence map›Paper›PMID 40127387›Full record

SynthesisBlood advances2025

Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review.

Aisling Barrett, Callum Harris, Toby A Eyre

Abstract readSystematic Review
In one paragraph

Synthesis in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. A Case of Pseudo-Richter Transformation Following Zanubrutinib Discontinuation in CLL.Mediterranean journal of hematology and infectious diseases · 2026
    Article
  5. The Evolving Therapeutic Landscape of Richter Transformation.Current hematologic malignancy reports · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aisling BarrettCancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.ORCID 0000-0002-6562-0767
Callum HarrisCancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Toby A EyreCancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.ORCID 0000-0002-6631-9749

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractThe disease shift of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL), so-called Richter transformation (RT), is a catastrophic clinical event. Rarely, survival can outperform expectations and accurate prognostication for patients may affect therapeutic choices. To date, prognosis has relied on readily available factors such as TP53 disruption, previous CLL treatment status, and performance score. Recently, a shared clonality assessment by immunoglobulin heavy-chain variable region gene (IgHV) sequencing of the CLL and RT has been considered therapeutically relevant, but this is infrequently performed. We performed a systematic review of peer-reviewed manuscripts where outcomes in relation to clonal relatedness and lack thereof (clonally related and clonally unrelated RT-DLBCL) were examined. Fifteen manuscripts that included 336 patients were found, of which 6 compared survival outcomes between the 2 groups in a statistically meaningful way. Two analyses showed no difference in survival outcomes with 4 studies reporting a significantly poorer prognosis with clonally related RT-DLBCL. In 2 of these studies, the baseline characteristics of clonally related and clonally unrelated groups were compared and the clonally related cases were enriched for underlying CLL, which was TP53 disrupted, IgHV unmutated, more heavily pretreated, and exhibiting stereotyped B-cell receptor VH CDR3 and RT-DLBCL, which was MYD88 wild type. We demonstrate that although clonal relatedness of the underlying CLL confers a poorer survival, this is not demonstrated in any study to be independent of other well-described clinical and genomic variables known to influence outcomes in RT-DLBCL. Further independent validation of this prognostic factor is required to help guide universal adoption into clinical practice.

Indexed as

Biomarkers, TumorCell Transformation, NeoplasticLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, DiffuseClonal EvolutionHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionPrognosisBiomarkers, TumorImmunoglobulin Heavy ChainsImmunoglobulin Variable Region

Identifiers

PMID40127387
PMCPMC12166378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.